LL-37 is implicated in the pathogenesis of lupus, psoriasis, and other autoimmune conditions — it can trigger or worsen flares. Anyone with an autoimmune diagnosis must consult a physician before use.
COMPOUND PROFILE · PEPPERLEDGER
LL-37
Type
Naturally occurring 37-amino-acid antimicrobial peptide — the sole human cathelicidin
Short plasma half-life; locally produced and acts at sites of infection/injury
Most studied use
Wound healing · Antimicrobial defense · Gut barrier health · Respiratory infections · Immune optimization
Regulatory status
Not FDA-approved for systemic use · Under Phase I/II investigation for wound healing and respiratory infections · Research chemical
Human evidence
Moderate — Phase I/II trials for wound healing and respiratory applications; no approved indication yet
Preclinical evidence
Exceptional — 25+ years as one of the most studied antimicrobial peptides; extensive mechanistic literature
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
What is LL-37?
LL-37 is the only antimicrobial peptide encoded in the human cathelicidin gene family — a distinction that makes it unique among all peptides in this guide. Your body produces LL-37 naturally as part of innate immune defense, releasing it from neutrophils, epithelial cells, and keratinocytes at sites of infection and injury. It's your first-line antimicrobial response at mucosal surfaces, skin, and wounds — killing bacteria, fungi, and viruses directly while simultaneously signaling the immune system to mount a coordinated adaptive response.
The biohacker appeal is broad. LL-37 sits at the intersection of three applications that consistently attract sophisticated users: immune optimization, wound healing, and gut health. On immune optimization: LL-37 modulates both innate and adaptive immunity, similar in therapeutic scope to Thymosin Alpha-1 but through an entirely different mechanism. On wound healing: LL-37 promotes angiogenesis, keratinocyte migration, and tissue repair through pathways that complement BPC-157's mechanism. On gut health: LL-37 is produced by intestinal epithelial cells and plays a role in maintaining gut barrier integrity.
The clinical evidence is in earlier stages — Phase I/II trials for wound healing and respiratory applications — but the mechanistic literature is exceptionally deep. LL-37 has been studied intensively for 25+ years as a drug candidate for antibiotic-resistant infections and wound care. The challenge has been delivery: LL-37 is rapidly degraded by proteases, making stable formulation difficult. This is why it's still in trials rather than approved.
How it works
Direct Antimicrobial Action
LL-37 is a cationic, amphipathic peptide that disrupts bacterial cell membranes via electrostatic interaction. The positively charged peptide binds to the negatively charged bacterial membrane, inserts into the lipid bilayer, and forms pores or causes membrane dissolution. Effective against gram-positive bacteria (S. aureus, Streptococcus), gram-negative bacteria (E. coli, P. aeruginosa), fungi (Candida), and some viruses. Crucially, because the mechanism targets membrane composition rather than specific metabolic pathways, antibiotic resistance is less likely to develop against LL-37.
Immunomodulation and Wound Healing
LL-37 activates TLR signaling, promotes dendritic cell maturation, stimulates chemokine production, and modulates inflammatory NF-κB activation. For wound healing: it stimulates keratinocyte migration and proliferation (re-epithelialization), promotes angiogenesis via VEGF upregulation, activates fibroblast migration, and reduces biofilm formation. This mechanism complements BPC-157's FAK-paxillin and VEGFR2/eNOS mechanisms.
Gut Epithelial Function
LL-37 is constitutively produced by intestinal epithelial cells and is a key regulator of gut barrier integrity. It modulates gut microbiome composition, prevents pathogen translocation across the epithelial layer, and regulates gut immune responses. Deficiency in gut LL-37 is associated with increased gut permeability and inflammatory bowel conditions.
What the research shows
HUMAN AND MECHANISTIC EVIDENCE
STUDYPeptides · 2011
LL-37 in Chronic Wound Healing — Phase I/II Trial
Ramos R, Silva JP, Rodrigues AC et al.
Phase I/II in venous leg ulcers. LL-37 topical application accelerated wound healing vs. placebo. Confirmed angiogenesis promotion and keratinocyte activation in human wound tissue. Key clinical evidence for the wound healing application.
LL-37 Promotes Wound Healing by Stimulating Keratinocyte Migration
Heilborn JD, Nilsson MF, Kratz G et al.
Established that LL-37 stimulates keratinocyte migration in human wound models. Foundational wound healing mechanism study. Re-epithelialization mechanism confirmed.
The Human Cathelicidin LL-37 as a Regulator of Inflammation and Host Defense
Vandamme D, Landuyt B, Luyten W, Schoofs L.
Comprehensive review of LL-37's dual roles in antimicrobial defense and immune modulation. Covers the breadth of mechanisms and clinical implications. Standard reference for LL-37 biology — 25 years of research synthesized.
?Antibiotic-resistant infection applications in humans (compelling mechanism, limited clinical trial)
?Gut health effects at injectable doses vs. locally produced quantities
What the community reports
—Reduced frequency and severity of infections — the most consistently noted effect; users describe getting sick less often, similar to Thymosin Alpha-1 reports
—Wound and injury healing acceleration — users with chronic wounds or slow-healing injuries report improvements consistent with clinical wound healing data
—Gut health improvement — reduced bloating, better gut comfort; consistent with the gut epithelial mechanism
—Injection site reactions more common than with most peptides — LL-37 has local antimicrobial activity at the injection site; local redness and discomfort more frequently reported; rotate sites
—Often stacked with BPC-157 for wound healing — complementary mechanisms are theorized to be synergistic
Common misconceptions
"LL-37 replaces antibiotics."
REALITY
LL-37 has broad-spectrum antimicrobial activity and low resistance-development risk. But it is not a replacement for conventional antibiotics in active serious infections — its clinical application is complement and prevention, not replacement. For serious infections requiring antibiotics, see a physician.
"LL-37 stimulates the immune system uniformly."
REALITY
LL-37 modulates immune responses — it can both activate and dampen different aspects of immune activity depending on context. In autoimmune conditions, LL-37 can trigger flares — it's implicated in lupus and psoriasis pathology. Anyone with autoimmune conditions should not use LL-37 without specialist guidance.
"LL-37 is just like BPC-157 for wound healing."
REALITY
Both promote wound healing but through different mechanisms. BPC-157 works via FAK-paxillin fibroblast migration and VEGFR2/eNOS angiogenesis. LL-37 works via keratinocyte migration, VEGF-mediated angiogenesis, and antimicrobial defense at the wound site. They're complementary, not redundant.
IMMUNE STACK
Thymosin Alpha-1 addresses adaptive immunity via T-cell maturation and dendritic cell enhancement. LL-37 addresses innate immunity via direct antimicrobial action and TLR-mediated immune coordination. For wound healing: BPC-157 provides complementary FAK-paxillin and VEGFR2 mechanisms.
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI COACH PREVIEW
I want to stack LL-37 with BPC-157 for a chronic wound. How should I structure the protocol?
The LL-37 + BPC-157 wound healing stack is mechanistically well-reasoned — these two compounds address wound healing from different but complementary angles. Here's how to structure it. The mechanisms: BPC-157 works primarily via FAK-paxillin fibroblast migration (getting repair cells to the site) and VEGFR2/eNOS angiogenesis (new blood vessels to supply the wound). LL-37 works via keratinocyte migration (re-epithelialization of the wound surface), VEGF-mediated angiogenesis (a parallel angiogenic pathway), and critically — antimicrobial defense at the wound site itself, which BPC-157 doesn't provide. Together they cover: vascularization, tissue matrix repair, surface epithelialization, and infection control. Protocol structure: BPC-157: 250 mcg subcutaneous, injected near the wound site or IM, once or twice daily. This is the standard BPC-157 wound protocol. LL-37: 100–250 mcg subcutaneous near the wound site, once daily. Start at 100 mcg and assess injection site reaction — LL-37 causes more local irritation than BPC-157 due to its membrane-disrupting activity. Rotate injection sites within the wound periphery. Timing: run both simultaneously — there's no pharmacokinetic reason to separate them. Injection near the wound site (subcutaneous in the surrounding tissue) concentrates both compounds where they're most needed. Duration: 4–8 weeks of consistent use. Wound healing is a weeks-to-months process — consistency matters more than acute dosing decisions. Important qualification: LL-37 is contraindicated in autoimmune conditions — if the wound is related to any inflammatory or autoimmune etiology, get medical guidance before adding LL-37. What's the nature of the wound — is it a surgical wound, injury, or chronic non-healing condition? That context matters for refining the protocol.
CONTINUE IN THE APP
Open PepperLedger to track your LL-37 protocol →
Free to join. No credit card. Ask the Coach about your LL-37 protocol once you're in.
Free to join · No credit card · 23-day Pro trial included